Revive Therapeutics Ltd (RVV:CC) | Stock Information | Vox Markets
Vox Markets

Revive Therapeutics Ltd

RVV:CC

Recent News

CompanyTitleDate
RVVRevive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases1 week ago
RVVRevive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research StudyAug 20, 2026
RVVRevive Therapeutics Announces Proposed Shares for Debt SettlementAug 19, 2026
RVVRevive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics PortfolioAug 19, 2026
RVVRevive Therapeutics Reports Grant of OptionsAug 14, 2026
RVVRevive Therapeutics Announces Closing of First Tranche of Non-Brokered Private PlacementJul 16, 2026
RVVREVIVE THERAPEUTICS ANNOUNCES PROPOSED PRIVATE PLACEMENTJul 3, 2026
RVVRVV Form 7-Monthly Progress Report-May-2026Jun 4, 2026
RVVRVV Form 5 Quarterly Listing Statement-Q3-Mar31-2026Jun 3, 2026
RVVRVV Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical CountermeasuresMay 20, 2026
RVVRVV Form7-MonthlyProgressReport-April-2026May 6, 2026
RVVRVV Form 7-Monthly Progress Report-March-2026Apr 7, 2026

Overview

Classification

Sector Healthcare

Industry Pharmaceuticals

Subindustry Pharmaceutical Manufacturers - Specialty & Generic

Financials